Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 7/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29424266 | 1.00 | HTR4 (0.65) | HTR4 | |
| SCHEMBL678433 | 1.00 | HTR4 (0.65) | HTR4 | |
| SCHEMBL29889091 | 1.00 | HTR4 (0.65) | HTR4 | |
| Hydrochloric Acid SCHEMBL7309004 | 0.99 | HTR4 (0.64) | HTR4 | |
| SCHEMBL4543915 | 0.91 | HTR4 (0.67) | HTR4 | |
| Dazopride SCHEMBL184075 | 0.83 | HTR4 (0.72) | HTR4 | |
| Dazopride SCHEMBL7339808 | 0.82 | HTR4 (0.71) | HTR4 | |
| SCHEMBL5077815 | 0.82 | DRD2 (0.43) | HTR4 | |
| SCHEMBL2522742 | 0.81 | DRD4 (0.58) | HTR4 | |
| Hydrochloric Acid SCHEMBL7309340 | 0.81 | DRD4 (0.57) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5229942-A | — | — | None | — | — | JP | disclosed |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2011091033-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011063115-A1 | COMBINATION OF NOOTROPIC AGENT WITH ONE OR MORE NEUROGENIC OR NEUROGENIC SENSITIZING AGENTS FOR STIMULATING OR INCREASING NEUROGENESIS | BRAINCELLS INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2010099217-A1 | MODULATION OF NEUROGENESIS USING D-CYCLOSERINE COMBINATIONS | BRAINCELLS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| EP-2125017-A2 | MODULATION OF NEUROGENESIS WITH USE OF MODAFINIL | Braincells, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-2076288-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS | Braincells, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-2068872-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | Braincells, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-2026813-A2 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | Braincells, Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134136-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007134077-A2 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | disclosed |
| JP-H05229942-A | IMPROVER FOR KINETIC FUNCTION OF DIGESTIVE TRACT | TEIKOKU CHEM IND CORP LTD | 1993-09-07 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.